Candriam SCA’s Global Blood Therapeutics, Inc. GBT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-360,956
| Closed | -$24.6M | – | 912 |
|
|
2022
Q3 | $24.6M | Sell |
360,956
-418,735
| -54% | -$23.1M | 0.17% | 130 |
|
|
2022
Q2 | $24.9M | Buy |
779,691
+22,983
| +3% | +$673K | 0.21% | 117 |
|
|
2022
Q1 | $26.2M | Buy |
756,708
+108,369
| +17% | +$3.24M | 0.18% | 130 |
|
|
2021
Q4 | $19M | Buy |
648,339
+314,298
| +94% | +$9.74M | 0.12% | 184 |
|
|
2021
Q3 | $8.51M | Buy |
334,041
+137,711
| +70% | +$4.05M | 0.06% | 303 |
|
|
2021
Q2 | $6.88M | Buy |
+196,330
| New | +$7.67M | 0.05% | 343 |
|
|
2020
Q3 | – | Sell |
-67,843
| Closed | -$4.28M | – | 836 |
|
|
2020
Q2 | $4.28M | Buy |
67,843
+22,843
| +51% | +$1.57M | 0.05% | 364 |
|
|
2020
Q1 | $3.5M | Hold |
45,000
| – | – | 0.04% | 430 |
|
|
2019
Q4 | $3.58M | Buy |
+45,000
| New | +$2.67M | 0.04% | 444 |
|
|
2019
Q1 | – | Sell |
-96,000
| Closed | -$3.94M | – | 843 |
|
|
2018
Q4 | $3.94M | Sell |
96,000
-68,000
| -41% | -$2.55M | 0.06% | 325 |
|
|
2018
Q3 | $6.23M | Buy |
164,000
+73,000
| +80% | +$3.23M | 0.08% | 277 |
|
|
2018
Q2 | $4.11M | Buy |
91,000
+14,000
| +18% | +$637K | 0.07% | 336 |
|
|
2018
Q1 | $3.72M | Sell |
77,000
-30,000
| -28% | -$1.67M | 0.06% | 339 |
|
|
2017
Q4 | $4.21M | Buy |
107,000
+10,000
| +10% | +$373K | 0.07% | 299 |
|
|
2017
Q3 | $3.01M | Buy |
97,000
+14,000
| +17% | +$394K | 0.05% | 369 |
|
|
2017
Q2 | $2.27M | Buy |
83,000
+6,000
| +8% | +$179K | 0.04% | 442 |
|
|
2017
Q1 | $2.84M | Hold |
77,000
| – | – | 0.05% | 372 |
|
|
2016
Q4 | $1.11M | Buy |
77,000
+17,000
| +28% | +$299K | 0.03% | 501 |
|
|
2016
Q3 | $1.38M | Buy |
60,000
+25,000
| +71% | +$476K | 0.03% | 435 |
|
|
2016
Q2 | $581K | Buy |
+35,000
| New | +$706K | 0.02% | 535 |
|
Other funds holding GBT
Candriam SCA's GBT Position: Q4 2022 in Review
Candriam SCA sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 360,956 shares — an estimated $24.6M sold.
Candriam SCA first reported a position in GBT in Q2 2016 and held it in 20 quarters. The position peaked at $26.2M in Q1 2022. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.
- Candriam SCA reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
- Candriam SCA sold 360,956 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $24.6M.
- Candriam SCA first reported a position in Global Blood Therapeutics, Inc. in Q2 2016 and held it in 20 quarters.
- Candriam SCA's Global Blood Therapeutics, Inc. position peaked at $26.2M in Q1 2022.
- 2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.
Based on Candriam SCA's 13F filing for Q4 2022, filed 13 Feb 2023.